Items Tagged ‘HR+’

May 31st, 2017

FDA Approves First-of-its-kind Kisqali® Femara® Co-Pack For Initial Treatment Of HR+/HER2- Advanced or Metastatic Breast Cancer

By

The US Food and Drug Administration (FDA) has approved the Kisqali ®Femara ® Co-Pack (ribociclib tablets; letrozole tablets) for the treatment of hormone receptor-positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer in postmenopausal women 1. The Kisqali-Femara Co-Pack is the first, and only currently available, combination pack with two prescription products in advanced breast […]

View full entry

Tags: Advanced Metastatic Breast Cancer, Breast Cancer, HER2 neu negative, HR+, Kisqali® Femara®, News


June 7th, 2016

Treatment with Aromatase Inhibitors for 10 Years Improves Cancer-Free Survival in Breast Cancer

By

Among postmenopausal women with hormone-positive, early breast cancer, treatment with aromatase inhibitors (AIs) for 10 years significantly improves cancer-free survival, compared to the 5-year standard length of AI treatment.  However, quality of life issues, bone density concerns, and a patient’s risk of a recurrence should be taken into consideration to determine the optimal length of […]

View full entry

Tags: AIs, aromatase inhibitors, Breast Cancer, early-stage, hormone-positive, HR+, News, postmenopausal, Stage I Node Negative Breast Cancer, survival


October 9th, 2015

Abemaciclib Receives FDA Breakthrough Therapy Designation in Advanced Breast Cancer

By

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to abemaciclib, a cyclin-dependent kinase (CDK) 4 and 6 inhibitor, for patients with refractory hormone-receptor-positive (HR+) advanced or metastatic breast cancer. According to the FDA, Breakthrough Therapy Designation is a process designed to expedite the development and review of drugs that are intended […]

View full entry

Tags: abemaciclib, Breast Cancer, CDK, hormone-receptor positive, HR+, metastatic, Metastatic Breast Cancer, MONARCH 3, News, Recurrent Breast Cancer